FDA approval of a new treatment is a significant positive catalyst for pharmaceutical companies. It not only opens up a new revenue stream but also enhances the company's reputation in the industry. For Teva, this approval could lead to increased sales and potentially improve its market position in the arthritis treatment sector, thus positively impacting its stock price in the short term.